China Pharma Holdings Inc (CPHI) FinancialsCPHIChina Pharma Holdings Inc

China Pharma Holdings Inc (CPHI) generates its revenue primarily from Domestic Pharmaceuticals, which accounts for 100.0% of total sales, equivalent to $983.54K. Understanding this concentration is critical for investors evaluating how CPHI navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, China Pharma Holdings Inc maintains a gross margin of 8.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -150.98%, while the net margin is -153.76%. These profitability ratios, combined with a Return on Equity (ROE) of -20.99%, provide a clear picture of how effectively CPHI converts its operational activities into shareholder value.

In the context of the broader market, CPHI competes directly with industry leaders such as BLRX and ACTU. With a market capitalization of $42.16M, it holds a significant position in the sector. When comparing efficiency, CPHI's gross margin of 8.81% stands against BLRX's 79.38% and ACTU's N/A. Such benchmarking helps identify whether China Pharma Holdings Inc is trading at a premium or discount relative to its financial performance.

The company has reported a net income loss of $1,458,123 in Q2 2026, with a negative net margin of -153.76%. The gross margin has fluctuated, but currently stands at 8.81%, which is low for sustainable growth. The forward P/E ratio is 1.5581, indicating potential for future earnings, but the current financials are concerning.